Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CUE |
---|---|---|
09:32 ET | 7406 | 1.74 |
09:34 ET | 200 | 1.71 |
09:36 ET | 3000 | 1.72 |
09:41 ET | 200 | 1.7 |
09:45 ET | 200 | 1.72 |
09:48 ET | 483 | 1.71 |
09:52 ET | 575 | 1.725 |
09:54 ET | 1000 | 1.7399 |
10:01 ET | 1100 | 1.73 |
10:03 ET | 1455 | 1.74 |
10:06 ET | 3028 | 1.77 |
10:10 ET | 1426 | 1.76 |
10:12 ET | 400 | 1.74 |
10:14 ET | 1000 | 1.7209 |
10:15 ET | 919 | 1.73 |
10:24 ET | 400 | 1.72 |
10:26 ET | 1000 | 1.72 |
10:30 ET | 200 | 1.72 |
10:35 ET | 319 | 1.7006 |
10:37 ET | 100 | 1.7 |
10:44 ET | 1000 | 1.71 |
10:48 ET | 371 | 1.71 |
10:50 ET | 300 | 1.7 |
10:57 ET | 100 | 1.71 |
11:02 ET | 919 | 1.71 |
11:06 ET | 2060 | 1.705 |
11:08 ET | 426 | 1.705 |
11:09 ET | 100 | 1.7 |
11:11 ET | 1100 | 1.7 |
11:13 ET | 100 | 1.69 |
11:20 ET | 100 | 1.69 |
11:26 ET | 100 | 1.69 |
11:27 ET | 100 | 1.69 |
11:33 ET | 2482 | 1.7 |
11:36 ET | 200 | 1.702 |
11:38 ET | 200 | 1.71 |
11:42 ET | 1500 | 1.7 |
11:44 ET | 101 | 1.68 |
11:45 ET | 100 | 1.68 |
11:51 ET | 484 | 1.685 |
11:56 ET | 100 | 1.67 |
12:00 ET | 2483 | 1.68 |
12:02 ET | 100 | 1.67 |
12:03 ET | 2926 | 1.685 |
12:12 ET | 200 | 1.7 |
12:18 ET | 100 | 1.68 |
12:21 ET | 100 | 1.7 |
12:23 ET | 500 | 1.69 |
12:34 ET | 279 | 1.69 |
12:39 ET | 198 | 1.6821 |
12:41 ET | 300 | 1.7 |
12:45 ET | 100 | 1.7 |
12:50 ET | 1926 | 1.69 |
12:54 ET | 100 | 1.68 |
12:57 ET | 100 | 1.68 |
12:59 ET | 200 | 1.68 |
01:01 ET | 381 | 1.69 |
01:06 ET | 550 | 1.68 |
01:14 ET | 3480 | 1.72 |
01:24 ET | 100 | 1.71 |
01:32 ET | 100 | 1.71 |
01:35 ET | 100 | 1.71 |
01:42 ET | 100 | 1.71 |
01:44 ET | 184 | 1.71 |
01:46 ET | 200 | 1.72 |
01:50 ET | 730 | 1.715 |
01:51 ET | 200 | 1.715 |
01:53 ET | 500 | 1.71 |
02:04 ET | 500 | 1.71 |
02:08 ET | 101 | 1.7 |
02:11 ET | 200 | 1.71 |
02:13 ET | 544 | 1.7 |
02:15 ET | 400 | 1.69 |
02:20 ET | 200 | 1.69 |
02:24 ET | 100 | 1.69 |
02:26 ET | 200 | 1.69 |
02:27 ET | 105 | 1.69 |
02:33 ET | 100 | 1.708 |
02:36 ET | 100 | 1.69 |
02:40 ET | 100 | 1.69 |
02:44 ET | 100 | 1.695 |
02:47 ET | 100 | 1.695 |
02:49 ET | 3100 | 1.68 |
02:54 ET | 300 | 1.69 |
02:56 ET | 100 | 1.68 |
03:02 ET | 1330 | 1.685 |
03:03 ET | 100 | 1.68 |
03:05 ET | 100 | 1.68 |
03:09 ET | 100 | 1.68 |
03:12 ET | 100 | 1.68 |
03:14 ET | 200 | 1.685 |
03:16 ET | 144 | 1.68 |
03:18 ET | 100 | 1.68 |
03:20 ET | 100 | 1.68 |
03:23 ET | 100 | 1.68 |
03:25 ET | 6485 | 1.67 |
03:27 ET | 200 | 1.67 |
03:36 ET | 377 | 1.66 |
03:39 ET | 100 | 1.66 |
03:41 ET | 1605 | 1.67 |
03:43 ET | 722 | 1.67 |
03:45 ET | 200 | 1.6708 |
03:48 ET | 400 | 1.67 |
03:50 ET | 142 | 1.67 |
03:52 ET | 1679 | 1.68 |
03:54 ET | 300 | 1.68 |
03:56 ET | 5997 | 1.7 |
03:57 ET | 805 | 1.7 |
03:59 ET | 20785 | 1.71 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Cue Biopharma Inc | 84.6M | -1.6x | --- |
Armata Pharmaceuticals Inc | 95.8M | -1.2x | --- |
LAVA Therapeutics NV | 72.6M | -1.7x | --- |
Jaguar Health Inc | 84.1M | -0.1x | --- |
Clearside Biomedical Inc | 97.9M | -2.4x | --- |
Kronos Bio Inc | 59.0M | -0.5x | --- |
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $84.6M |
---|---|
Revenue (TTM) | $7.0M |
Shares Outstanding | 48.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.99 |
EPS | $-1.07 |
Book Value | $0.79 |
P/E Ratio | -1.6x |
Price/Sales (TTM) | 12.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -732.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.